The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular residual disease detection using whole-genome sequencing-based ctDNA assay for resectable colorectal cancer in the MONSTAR-SCREEN-3 project.
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical; Takeda Science Foundation
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Yuichiro Tsukada
Research Funding - Exact Sciences (Inst)
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly
 
Yusuke Suwa
No Relationships to Disclose
 
Nobuhisa Matsuhashi
Honoraria - Abbott Japan; Alfresa Pharma Corporation; Amco; Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; EA Pharma; Eisai; Guardant Health; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Kyowa Kirin; Lilly Japan; MC Medical; Merck KGaA; Miyarisan pharmaceutical; MSD; Novartis; Olympus Marketing, Inc.; Ono Pharmaceutical; Stryker; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Covidien (Inst); e-NA Biotec Inc. (Inst); EPS Corporation (Inst); JMS (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Toray Industries (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Yasuki Akiyama
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Koji Ando
Honoraria - Merck
 
Akiyoshi Kanazawa
No Relationships to Disclose
 
Koji Komori
No Relationships to Disclose
 
Yoshifumi Shimada
No Relationships to Disclose
 
Yuki Matsubara
Honoraria - Bristol Myers Squibb; MSD; Taiho Pharmaceutical
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Jeff Jasper
Employment - Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
Travel, Accommodations, Expenses - Myriad Genetics
 
Katherine Taber
Employment - Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
Travel, Accommodations, Expenses - Myriad Genetics
 
Dale Muzzey
Employment - Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
Travel, Accommodations, Expenses - Myriad Genetics
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health